Androgen decline and outcome in castration resistant prostate cancer (mCRPC) patients treated with docetaxel (Doc), prednisone +/- bevacizumab (B) Meeting Abstract
| Authors: | Ryan, C. J.; Dutta, S.; Kelly, W.; Morris, M. J.; Taplin, M. E.; Halabi, S. |
| Abstract Title: | Androgen decline and outcome in castration resistant prostate cancer (mCRPC) patients treated with docetaxel (Doc), prednisone +/- bevacizumab (B) |
| Meeting Title: | 43rd ESMO Congress (ESMO 2018) |
| Journal Title: | Annals of Oncology |
| Volume: | 29 |
| Issue: | Suppl. 8 |
| Meeting Dates: | 2018 Oct 19-23 |
| Meeting Location: | Munich, Germany |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2018-10-01 |
| Start Page: | mdy284.025 |
| Language: | English |
| ACCESSION: | WOS:000459277301395 |
| PROVIDER: | wos |
| DOI: | 10.1093/annonc/mdy284.025 |
| Notes: | Meeting Abstract: 816P -- Appears on page viii283 of the abstract book -- Source: Wos |
